67 related articles for article (PubMed ID: 26807861)
1. Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products.
Park H; Lee S; Hong S
J Nat Prod; 2016 Feb; 79(2):293-9. PubMed ID: 26807861
[TBL] [Abstract][Full Text] [Related]
2. Structure-based de novo design and identification of D816V mutant-selective c-KIT inhibitors.
Park H; Lee S; Lee S; Hong S
Org Biomol Chem; 2014 Jul; 12(26):4644-55. PubMed ID: 24853767
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening.
Shin S; Mah S; Hong S; Park H
J Chem Inf Model; 2016 Apr; 56(4):802-10. PubMed ID: 27014917
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Vendôme J; Letard S; Martin F; Svinarchuk F; Dubreuil P; Auclair C; Le Bret M
J Med Chem; 2005 Oct; 48(20):6194-201. PubMed ID: 16190746
[TBL] [Abstract][Full Text] [Related]
5. Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.
Lee S; Lee H; Kim J; Lee S; Kim SJ; Choi BS; Hong SS; Hong S
J Med Chem; 2014 Aug; 57(15):6428-43. PubMed ID: 25004409
[TBL] [Abstract][Full Text] [Related]
6. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
7. Natural products active in aberrant c-Kit signaling.
Henrich CJ; Goncharova EI; Wilson JA; Gardella RS; Johnson TR; McMahon JB; Takada K; Bokesch HR; Gustafson KR
Chem Biol Drug Des; 2007 May; 69(5):321-30. PubMed ID: 17539824
[TBL] [Abstract][Full Text] [Related]
8. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
9. Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design.
Park H; Hong S; Kim J; Hong S
J Am Chem Soc; 2013 Jun; 135(22):8227-37. PubMed ID: 23679864
[TBL] [Abstract][Full Text] [Related]
10. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.
Bougherara H; Subra F; Crépin R; Tauc P; Auclair C; Poul MA
Mol Cancer Res; 2009 Sep; 7(9):1525-33. PubMed ID: 19737976
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel
Elasbali AM; Al-Soud WA; Elfaki EM; Alanazi HH; Alharbi B; Alharethi SH; Anwer K; Mohammad T; Hassan MI
J Biomol Struct Dyn; 2024 Jul; 42(11):5982-5994. PubMed ID: 37403288
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
14. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
Bougherara H; Georgin-Lavialle S; Damaj G; Launay JM; Lhermitte L; Auclair C; Arock M; Dubreuil P; Hermine O; Poul MA
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):62-9. PubMed ID: 23127495
[TBL] [Abstract][Full Text] [Related]
15. Computer simulations reveal a novel nucleotide-type binding orientation for ellipticine-based anticancer c-kit kinase inhibitors.
Thompson D; Miller C; McCarthy FO
Biochemistry; 2008 Sep; 47(39):10333-44. PubMed ID: 18754682
[TBL] [Abstract][Full Text] [Related]
16. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
[TBL] [Abstract][Full Text] [Related]
17. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
18. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
[TBL] [Abstract][Full Text] [Related]
20. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors.
Kansal N; Silakari O; Ravikumar M
Eur J Med Chem; 2010 Jan; 45(1):393-404. PubMed ID: 19892442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]